SIMCERE PHARMAC (Germany) Performance
| S2P Stock | EUR 1.27 0.01 0.78% |
The entity has a beta of 0.82, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, SIMCERE PHARMAC's returns are expected to increase less than the market. However, during the bear market, the loss of holding SIMCERE PHARMAC is expected to be smaller as well. At this point, SIMCERE PHARMAC GRP has a negative expected return of -0.0431%. Please make sure to validate SIMCERE PHARMAC's total risk alpha, maximum drawdown, skewness, as well as the relationship between the treynor ratio and potential upside , to decide if SIMCERE PHARMAC GRP performance from the past will be repeated at future time.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days SIMCERE PHARMAC GRP has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, SIMCERE PHARMAC is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Price Earnings Ratio | 26.2 | |
| Dividend Yield | 0.0182 | |
| Payout Ratio | 0.3848 |
SIMCERE |
SIMCERE PHARMAC Relative Risk vs. Return Landscape
If you would invest 135.00 in SIMCERE PHARMAC GRP on October 1, 2025 and sell it today you would lose (8.00) from holding SIMCERE PHARMAC GRP or give up 5.93% of portfolio value over 90 days. SIMCERE PHARMAC GRP is currently producing negative expected returns and takes up 3.3554% volatility of returns over 90 trading days. Put another way, 30% of traded stocks are less volatile than SIMCERE, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
SIMCERE PHARMAC Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for SIMCERE PHARMAC's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as SIMCERE PHARMAC GRP, and traders can use it to determine the average amount a SIMCERE PHARMAC's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0128
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | S2P |
Estimated Market Risk
| 3.36 actual daily | 30 70% of assets are more volatile |
Expected Return
| -0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average SIMCERE PHARMAC is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of SIMCERE PHARMAC by adding SIMCERE PHARMAC to a well-diversified portfolio.
SIMCERE PHARMAC Fundamentals Growth
SIMCERE Stock prices reflect investors' perceptions of the future prospects and financial health of SIMCERE PHARMAC, and SIMCERE PHARMAC fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on SIMCERE Stock performance.
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0344 | |||
| Profit Margin | 0.18 % | |||
| Operating Margin | 0.1 % | |||
| Shares Outstanding | 2.66 B | |||
| Revenue | 5.58 B | |||
| EBITDA | 743.59 M | |||
| Book Value Per Share | 2.31 X | |||
| Earnings Per Share | 0.05 X | |||
About SIMCERE PHARMAC Performance
By analyzing SIMCERE PHARMAC's fundamental ratios, stakeholders can gain valuable insights into SIMCERE PHARMAC's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if SIMCERE PHARMAC has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if SIMCERE PHARMAC has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about SIMCERE PHARMAC GRP performance evaluation
Checking the ongoing alerts about SIMCERE PHARMAC for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for SIMCERE PHARMAC GRP help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| SIMCERE PHARMAC GRP generated a negative expected return over the last 90 days | |
| SIMCERE PHARMAC GRP may become a speculative penny stock | |
| SIMCERE PHARMAC GRP has high historical volatility and very poor performance | |
| About 69.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing SIMCERE PHARMAC's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether SIMCERE PHARMAC's stock is overvalued or undervalued compared to its peers.
- Examining SIMCERE PHARMAC's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating SIMCERE PHARMAC's management team can have a significant impact on its success or failure. Reviewing the track record and experience of SIMCERE PHARMAC's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of SIMCERE PHARMAC's stock. These opinions can provide insight into SIMCERE PHARMAC's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for SIMCERE Stock analysis
When running SIMCERE PHARMAC's price analysis, check to measure SIMCERE PHARMAC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SIMCERE PHARMAC is operating at the current time. Most of SIMCERE PHARMAC's value examination focuses on studying past and present price action to predict the probability of SIMCERE PHARMAC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SIMCERE PHARMAC's price. Additionally, you may evaluate how the addition of SIMCERE PHARMAC to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |